journal
MENU ▼
Read by QxMD icon Read
search

Annals of the Rheumatic Diseases

journal
https://www.readbyqxmd.com/read/27913376/axial-disease-in-psoriatic-arthritis-study-defining-the-clinical-and-radiographic-phenotype-of-psoriatic-spondyloarthritis
#1
Deepak R Jadon, Raj Sengupta, Alison Nightingale, Mark Lindsay, Eleanor Korendowych, Graham Robinson, Amelia Jobling, Gavin Shaddick, Jing Bi, Robert Winchester, Jon T Giles, Neil J McHugh
OBJECTIVES: To compare the prevalence, clinical and radiographic characteristics of psoriatic spondyloarthritis (PsSpA) in psoriatic arthritis (PsA), with ankylosing spondylitis (AS). METHODS: A prospective single-centre cross-sectional observational study recruited consecutive PsA and AS cases. Participants completed outcome measures, and underwent clinical examination, axial radiographic scoring and HLA-sequencing. Multivariable analyses are presented. RESULTS: The 402 enrolled cases (201 PsA, 201 AS; fulfilling classification criteria for respective conditions) were reclassified based upon radiographic axial disease and psoriasis, as: 118 PsSpA, 127 peripheral-only PsA (pPsA), and 157 AS without psoriasis (AS) cases...
December 2, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27903508/the-patient-perspective-on-absence-of-disease-activity-in-rheumatoid-arthritis-a-survey-to-identify-key-domains-of-patient-perceived-remission
#2
Lilian H D van Tuyl, Martina Sadlonova, Sarah Hewlett, Bev Davis, Caroline Flurey, Niti Goel, Laure Gossec, Cecilie Heegaard Brahe, Catherine L Hill, Wijnanda Hoogland, John Kirwan, Merete L Hetland, Dirkjan van Schaardenburg, Josef S Smolen, Tanja Stamm, Marieke Voshaar, George A Wells, Maarten Boers
BACKGROUND: Guidelines suggest treatment in rheumatoid arthritis (RA) to target remission, in close consultation with the patient. Our recent qualitative study of the patients' perspective on remission in RA identified 26 domains. The current study aimed to identify a short list of the most important aspects to inform future research. METHODS: Patients with RA from the Netherlands, the UK, Austria, Denmark, France and the USA completed a survey that contained all domains identified in our qualitative study...
November 30, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27903507/hydroxychloroquine-inhibits-proinflammatory-signalling-pathways-by-targeting-endosomal-nadph-oxidase
#3
Nadine Müller-Calleja, Davit Manukyan, Antje Canisius, Dennis Strand, Karl J Lackner
OBJECTIVES: Hydroxychloroquine (HCQ) has been used for decades to treat patients with rheumatic diseases, for example, systemic lupus erythematosus (SLE), rheumatoid arthritis or the antiphospholipid syndrome (APS). We hypothesise that HCQ might target endosomal NADPH oxidase (NOX), which is involved in the signal transduction of cytokines as well as antiphospholipid antibodies (aPL). METHODS: For in vitro experiments, monocytic cells were stimulated with tumour necrosis factor α (TNFα), interleukin-1β (IL-1β) or a human monoclonal aPL and the activity of NOX was determined by flow cytometry...
November 30, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27899376/gwas-of-clinically-defined-gout-and-subtypes-identifies-multiple-susceptibility-loci-that-include-urate-transporter-genes
#4
Akiyoshi Nakayama, Hirofumi Nakaoka, Ken Yamamoto, Masayuki Sakiyama, Amara Shaukat, Yu Toyoda, Yukinori Okada, Yoichiro Kamatani, Takahiro Nakamura, Tappei Takada, Katsuhisa Inoue, Tomoya Yasujima, Hiroaki Yuasa, Yuko Shirahama, Hiroshi Nakashima, Seiko Shimizu, Toshihide Higashino, Yusuke Kawamura, Hiraku Ogata, Makoto Kawaguchi, Yasuyuki Ohkawa, Inaho Danjoh, Atsumi Tokumasu, Keiko Ooyama, Toshimitsu Ito, Takaaki Kondo, Kenji Wakai, Blanka Stiburkova, Karel Pavelka, Lisa K Stamp, Nicola Dalbeth, Yutaka Sakurai, Hiroshi Suzuki, Makoto Hosoyamada, Shin Fujimori, Takashi Yokoo, Tatsuo Hosoya, Ituro Inoue, Atsushi Takahashi, Michiaki Kubo, Hiroshi Ooyama, Toru Shimizu, Kimiyoshi Ichida, Nariyoshi Shinomiya, Tony R Merriman, Hirotaka Matsuo
OBJECTIVE: A genome-wide association study (GWAS) of gout and its subtypes was performed to identify novel gout loci, including those that are subtype-specific. METHODS: Putative causal association signals from a GWAS of 945 clinically defined gout cases and 1213 controls from Japanese males were replicated with 1396 cases and 1268 controls using a custom chip of 1961 single nucleotide polymorphisms (SNPs). We also first conducted GWASs of gout subtypes. Replication with Caucasian and New Zealand Polynesian samples was done to further validate the loci identified in this study...
November 29, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27899375/response-to-criteria-for-caps-is-it-all-in-the-name-by-touitou-and-sarrabay
#5
LETTER
Jasmin B Kuemmerle-Deschner, Susanne M Benseler
No abstract text is available yet for this article.
November 29, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27899374/an-induction-or-flare-of-arthritis-and-or-sacroiliitis-by-vedolizumab-in-inflammatory-bowel-disease-a-case-series
#6
G Varkas, K Thevissen, G De Brabanter, L Van Praet, F Czul-Gurdian, H Cypers, J De Kock, P Carron, M De Vos, P Hindryckx, J Arts, I Vanneuville, P Schoenaers, B Claerhout, M Abreu, F Van den Bosch, D Elewaut
BACKGROUND: In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to α4β7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the α4β7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of α4β7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis...
November 29, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27899373/influence-of-geolocation-and-ethnicity-on-the-phenotypic-expression-of-primary-sj%C3%A3-gren-s-syndrome-at-diagnosis-in-8310-patients-a-cross-sectional-study-from-the-big-data-sj%C3%A3-gren-project-consortium
#7
Pilar Brito-Zerón, Nihan Acar-Denizli, Margit Zeher, Astrid Rasmussen, Raphaele Seror, Elke Theander, Xiaomei Li, Chiara Baldini, Jacques-Eric Gottenberg, Debashish Danda, Luca Quartuccio, Roberta Priori, Gabriela Hernandez-Molina, Aike A Kruize, Valeria Valim, Marika Kvarnstrom, Damien Sene, Roberto Gerli, Sonja Praprotnik, David Isenberg, Roser Solans, Maureen Rischmueller, Seung-Ki Kwok, Gunnel Nordmark, Yasunori Suzuki, Roberto Giacomelli, Valerie Devauchelle-Pensec, Michele Bombardieri, Benedikt Hofauer, Hendrika Bootsma, Johan G Brun, Guadalupe Fraile, Steven E Carsons, Tamer A Gheita, Jacques Morel, Cristina Vollenveider, Fabiola Atzeni, Soledad Retamozo, Ildiko Fanny Horvath, Kathy Sivils, Thomas Mandl, Pulukool Sandhya, Salvatore De Vita, Jorge Sanchez-Guerrero, Eefje van der Heijden, Virginia Fernandes Moça Trevisani, Marie Wahren-Herlenius, Xavier Mariette, Manuel Ramos-Casals
OBJECTIVES: To analyse the influence of geolocation and ethnicity on the clinical presentation of primary Sjögren's syndrome (SjS) at diagnosis. METHODS: The Big Data Sjögren Project Consortium is an international, multicentre registry designed in 2014. By January 2016, 20 centres from five continents were participating. Multivariable logistic regression analyses were performed. RESULTS: We included 7748 women (93%) and 562 men (7%), with a mean age at diagnosis of primary SjS of 53 years...
November 29, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27899372/effect-of-rituximab-on-malignancy-risk-in-patients-with-anca-associated-vasculitis
#8
Emma E van Daalen, Raffaella Rizzo, Andreas Kronbichler, Ron Wolterbeek, Jan A Bruijn, David R Jayne, Ingeborg M Bajema, Chinar Rahmattulla
OBJECTIVES: Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated with cyclophosphamide have an increased malignancy risk compared with the general population. We investigated whether treatment with rituximab instead of cyclophosphamide has decreased the malignancy risk in patients with AAV. METHODS: The study included patients with AAV treated at a tertiary vasculitis referral centre between 2000 and 2014. The malignancy incidence in these patients was compared with the incidence in the general population by calculating standardised incidence ratios (SIRs), adjusted for sex, age and calendar year...
November 29, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27895041/infections-and-the-risk-of-incident-giant-cell-arteritis-a-population-based-case-control-study
#9
Rennie L Rhee, Peter C Grayson, Peter A Merkel, Gunnar Tomasson
OBJECTIVES: Alterations in the immune system and infections are suspected to increase susceptibility to giant cell arteritis (GCA). Recently herpes zoster has been directly implicated in the pathogenesis of GCA. We examined the association between prior infections, in particular herpes zoster, and incident GCA in a population-based cohort. METHODS: A nested case-control study was performed using an electronic database from the UK. Cases with newly diagnosed GCA were identified using a validated algorithm and compared with age-matched, sex-matched and practice-matched controls...
November 28, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27895040/the-role-of-non-invasive-cardiovascular-imaging-in-the-assessment-of-cardiovascular-risk-in-rheumatoid-arthritis-where-we-are-and-where-we-need-to-be
#10
REVIEW
Graham J Fent, John P Greenwood, Sven Plein, Maya H Buch
This review assesses the risk assessment of cardiovascular disease (CVD) in rheumatoid arthritis (RA) and how non-invasive imaging modalities may improve risk stratification in future. RA is common and patients are at greater risk of CVD than the general population. Cardiovascular (CV) risk stratification is recommended in European guidelines for patients at high and very high CV risk in order to commence preventative therapy. Ideally, such an assessment should be carried out immediately after diagnosis and as part of ongoing long-term patient care in order to improve patient outcomes...
November 28, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27888172/disease-activity-trajectories-in-early-axial-spondyloarthritis-results-from-the-desir-cohort
#11
Anna Molto, Sophie Tezenas du Montcel, Daniel Wendling, Maxime Dougados, Antoine Vanier, Laure Gossec
BACKGROUND: Disease activity may change over time in axial spondyloarthritis (axSpA). The objectives were to identify patterns of disease activity evolution in patients with early axSpA. METHODS: Patients from the prospective early axSpA cohort (DEvenir des Spondyloarthrites Indifférenciées Récentes (DESIR)) who fulfilled the Assessment in SpondyloArthritis Society (ASAS) criteria for axSpA at baseline and with at least three Ankylosing Spondylitis Disease Activity Score (ASDAS) values available over the 3 years of follow-up were analysed...
November 25, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27884822/a-framework-for-remission-in-sle-consensus-findings-from-a-large-international-task-force-on-definitions-of-remission-in-sle-doris
#12
Ronald van Vollenhoven, Alexandre Voskuyl, George Bertsias, Cynthia Aranow, Martin Aringer, Laurent Arnaud, Anca Askanase, Petra Balážová, Eloisa Bonfa, Hendrika Bootsma, Dimitrios Boumpas, Ian Bruce, Ricard Cervera, Ann Clarke, Cindy Coney, Nathalie Costedoat-Chalumeau, László Czirják, Ronald Derksen, Andrea Doria, Thomas Dörner, Rebecca Fischer-Betz, Ruth Fritsch-Stork, Caroline Gordon, Winfried Graninger, Noémi Györi, Frédéric Houssiau, David Isenberg, Soren Jacobsen, David Jayne, Annegret Kuhn, Veronique Le Guern, Kirsten Lerstrøm, Roger Levy, Francinne Machado-Ribeiro, Xavier Mariette, Jamil Missaykeh, Eric Morand, Marta Mosca, Murat Inanc, Sandra Navarra, Irmgard Neumann, Marzena Olesinska, Michelle Petri, Anisur Rahman, Ole Petter Rekvig, Jozef Rovensky, Yehuda Shoenfeld, Josef Smolen, Angela Tincani, Murray Urowitz, Bernadette van Leeuw, Carlos Vasconcelos, Anne Voss, Victoria P Werth, Helena Zakharova, Asad Zoma, Matthias Schneider, Michael Ward
OBJECTIVES: Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. METHODS: An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting...
November 24, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27884821/the-effect-of-different-durations-of-remission-on-damage-accrual-results-from-a-prospective-monocentric-cohort-of-caucasian-patients
#13
Margherita Zen, Luca Iaccarino, Mariele Gatto, Silvano Bettio, Francesca Saccon, Anna Ghirardello, Leonardo Punzi, Andrea Doria
AIM: To identify the shortest duration of remission associated with improved outcomes in systemic lupus erythematosus (SLE). METHODS: We studied 293 Caucasian patients with SLE during 7-year follow-up. Disease activity was assessed by SLE Disease Activity Index 2000 and damage by Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We defined three remission levels: complete, clinical off-corticosteroids, clinical on-corticosteroids (prednisone 1-5 mg/day)...
November 24, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27856432/efficacy-and-safety-of-sarilumab-monotherapy-versus-adalimumab-monotherapy-for-the-treatment-of-patients-with-active-rheumatoid-arthritis-monarch-a-randomised-double-blind-parallel-group-phase-iii-trial
#14
Gerd R Burmester, Yong Lin, Rahul Patel, Janet van Adelsberg, Erin K Mangan, Neil M H Graham, Hubert van Hoogstraten, Deborah Bauer, Juan Ignacio Vargas, Eun Bong Lee
OBJECTIVES: To compare efficacy and safety of sarilumab monotherapy with adalimumab monotherapy in patients with active rheumatoid arthritis (RA) who should not continue treatment with methotrexate (MTX) due to intolerance or inadequate response. METHODS: MONARCH was a randomised, active-controlled, double-blind, double-dummy, phase III superiority trial. Patients received sarilumab (200 mg every 2 weeks (q2w)) or adalimumab (40 mg q2w) monotherapy for 24 weeks...
November 17, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27852576/criteria-for-caps-is-it-all-in-the-name
#15
LETTER
Isabelle Touitou, Guillaume Sarrabay
No abstract text is available yet for this article.
November 16, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27836820/risk-of-diabetes-mellitus-associated-with-disease-modifying-antirheumatic-drugs-and-statins-in-rheumatoid-arthritis
#16
Gulsen Ozen, Sofia Pedro, Marie E Holmqvist, Michael Avery, Frederick Wolfe, Kaleb Michaud
OBJECTIVE: To investigate the rate of incident diabetes mellitus (DM) in patients with rheumatoid arthritis (RA) and the impact of disease-modifying antirheumatic drug (DMARD) and statin treatments. METHODS: We studied patients with RA and ≥1 year participation in the National Data Bank for Rheumatic Diseases without baseline DM from 2000 through 2014. DM was determined by self-report or initiating DM medication. DMARDs were categorised into four mutually exclusive groups: (1) methotrexate monotherapy (reference); (2) any abatacept with or without synthetic DMARDs (3) any other DMARDs with methotrexate; (4) all other DMARDs without methotrexate; along with separate statin, glucocorticoid and hydroxychloroquine (yes/no) variables...
November 11, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27821644/lesinurad-in-combination-with-allopurinol-a-randomised-double-blind-placebo-controlled-study-in-patients-with-gout-with-inadequate-response-to-standard-of-care-the-multinational-clear-2-study
#17
Thomas Bardin, Robert T Keenan, Puja P Khanna, Jeff Kopicko, Maple Fung, Nihar Bhakta, Scott Adler, Chris Storgard, Scott Baumgartner, Alexander So
OBJECTIVES: Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added to allopurinol in patients with serum uric acid (sUA) above target in a 12-month, randomised, phase III trial. METHODS: Patients on allopurinol ≥300 mg (≥200 mg in moderate renal impairment) had sUA level of ≥6.5 mg/dL (≥387 µmol/L) at screening and two or more gout flares in the prior year. Primary end point was the proportion of patients achieving sUA level of <6...
November 7, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27811148/response-to-jak-inhibition-in-sting-associated-interferonopathy-by-crow-et-al
#18
LETTER
Victoria Tüngler, Nadja König, Claudia Günther, Kerstin Engel, Christoph Fiehn, Martin Smitka, Maja von der Hagen, Reinhard Berner, Min Ae Lee-Kirsch
No abstract text is available yet for this article.
November 3, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27811147/development-of-the-autoinflammatory-disease-damage-index-addi
#19
Nienke M Ter Haar, Kim V Annink, Sulaiman M Al-Mayouf, Gayane Amaryan, Jordi Anton, Karyl S Barron, Susanne M Benseler, Paul A Brogan, Luca Cantarini, Marco Cattalini, Alexis-Virgil Cochino, Fabrizio De Benedetti, Fatma Dedeoglu, Adriana A De Jesus, Ornella Della Casa Alberighi, Erkan Demirkaya, Pavla Dolezalova, Karen L Durrant, Giovanna Fabio, Romina Gallizzi, Raphaela Goldbach-Mansky, Eric Hachulla, Veronique Hentgen, Troels Herlin, Michaël Hofer, Hal M Hoffman, Antonella Insalaco, Annette F Jansson, Tilmann Kallinich, Isabelle Koné-Paut, Anna Kozlova, Jasmin B Kuemmerle-Deschner, Helen J Lachmann, Ronald M Laxer, Alberto Martini, Susan Nielsen, Irina Nikishina, Amanda K Ombrello, Seza Ozen, Efimia Papadopoulou-Alataki, Pierre Quartier, Donato Rigante, Ricardo Russo, Anna Simon, Maria Trachana, Yosef Uziel, Angelo Ravelli, Marco Gattorno, Joost Frenkel
OBJECTIVES: Autoinflammatory diseases cause systemic inflammation that can result in damage to multiple organs. A validated instrument is essential to quantify damage in individual patients and to compare disease outcomes in clinical studies. Currently, there is no such tool. Our objective was to develop a common autoinflammatory disease damage index (ADDI) for familial Mediterranean fever, cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic fever syndrome and mevalonate kinase deficiency...
November 3, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27811146/pp2a-plays-a-key-role-in-inflammation-and-cancer-through-tristetraprolin-activation
#20
LETTER
Ion Cristóbal, Blanca Torrejón, Juan Madoz-Gúrpide, Federico Rojo, Jesús García-Foncillas
No abstract text is available yet for this article.
November 3, 2016: Annals of the Rheumatic Diseases
journal
journal
20039
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"